Shots:
- Kashiv BioSciences submitted a BLA to the US FDA and received EMA MAA acceptance for ADL-018, a proposed biosimilar to Xolair (omalizumab)
- ADL-018 is a humanized mAb biosimilar to Xolair (omalizumab), designed to block IgE binding on mast cells and basophils. Xolair is approved for CSU (≥12 yrs), moderate-to-severe asthma (≥6 yrs), chronic rhinosinusitis with nasal polyps (≥18 yrs), and IgE-mediated food allergy (≥1 yr)
- Alvotech partnered with Kashiv BioSciences to develop the proposed Xolair biosimilar known as AVT23 by Alvotech and ADL-018 by Kashiv for markets including the EEA, UK, Switzerland, Australia, New Zealand, and Canada
Ref: Businesswire| Image: Kashiv BioSciences | Press Release
Related News:- Kashiv BioSciences and JAMP Pharma Launch Pexegra (Biosimilar, Neulasta) and Filra (Biosimilar, Neupogen) in Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
